SIBO and Gut Motility (2026-04-21)
1 Pimentel et al. 2000 — SIBO Eradication Decreases CFS Symptoms (RCT)
Full Citation:: Pimentel M, Hallegua D, Chow EJ, Wallace D, Bonorris G, Lin HC. Eradication of small intestinal bacterial overgrowth decreases symptoms in chronic fatigue syndrome: a double blind, randomized study. Gastroenterology. 2000;118(4):A414. (Pimentel et al. 2000) DOI:: 10.1016/S0016-5085(00)83765-8 PMID:: Not indexed (conference abstract, Digestive Disease Week 2000) Article Type:: Double-blind, placebo-controlled RCT (conference abstract) Key Findings::
- n=31 CFS patients; 77% SIBO-positive by lactulose hydrogen breath test
- Neomycin vs placebo: no statistically significant difference between arms (underpowered)
- Breath test normalization correlated with symptom improvement in responders
- First controlled study demonstrating high SIBO prevalence in CFS and testing eradicationConclusion:: Supports the biological plausibility of SIBO as a comorbid contributor to CFS symptoms, but the RCT was insufficiently powered to demonstrate treatment efficacy. Limitations:: Conference abstract only; never published as full peer-reviewed paper. n=31 is severely underpowered. Lactulose breath test validity is contested (see Kashyap 2024). Study is 25+ years old; replication urgently needed. Conflict of interest not assessable (abstract). ME/CFS Relevance:: Provides the only (albeit low-quality) RCT evidence for SIBO eradication in CFS specifically. Supports biological rather than functional explanation for GI symptoms. The 77% SIBO prevalence figure should be cited cautiously given methodology limitations. Certainty Assessment::
- *Quality:* Low (conference abstract, never peer-reviewed as full paper)
- *Sample:* n=31
- *Replication:* Not independently replicated
- *Score:* 0.252 Pimentel et al. 2011 — Rifaximin for IBS-D: TARGET 1 and 2 RCTs
Full Citation:: Pimentel M, Lembo A, Chey WD, et al.; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32. (Pimentel et al. 2011) DOI:: 10.1056/NEJMoa1004409 PMID:: 21208106 Article Type:: Phase 3 double-blind RCT (two identically designed trials) Key Findings::
- Rifaximin 550 mg three times daily × 14 days vs placebo in IBS without constipation (IBS-D)
- Adequate relief of global IBS symptoms: 40.7% rifaximin vs 31.7% placebo (combined; p\<0.001)
- Significant relief of bloating, abdominal pain, loose/watery stools
- Effect maintained up to 10 weeks after treatment completion
- Rifaximin is minimally absorbed, acting locally in the gut lumen — low systemic adverse effectsConclusion:: Rifaximin provides modest but statistically significant and durable symptom relief in IBS-D, consistent with SIBO or dysbiosis as a contributing pathomechanism. Effect size is real but not large (NNT ≈ 11). Limitations:: IBS-D cohort, not ME/CFS-specific. Commercial funding by Salix Pharmaceuticals (disclosed). Effect size modest. Breath test not used for patient selection. Mechanism inferred (dysbiosis/SIBO), not confirmed. No long-term follow-up beyond 10 weeks. ME/CFS Relevance:: Provides highest-quality evidence that rifaximin is effective against presumed small intestinal dysbiosis — the closest proxy for SIBO treatment in ME/CFS patients who share IBS comorbidity. Supports rifaximin as a reasonable therapeutic option for ME/CFS patients with confirmed SIBO and IBS-D symptoms. Certainty Assessment::
- *Quality:* High (phase 3 RCT × 2, NEJM, large n)
- *Sample:* n≈1,200 combined
- *Replication:* Independently replicated across two trials; FDA approved
- *Score:* 0.753 Pimentel et al. 2009 — Prokinetics Delay SIBO Relapse
Full Citation:: Pimentel M, Morales W, Lezcano S, Sun-Chuan D, Low K, Yang J. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. Gastroenterol Hepatol (N Y). 2009;5(6):435–442. (Pimentel et al. 2009) DOI:: Not available PMID:: 20574504 | PMC: PMC2886395 Article Type:: Retrospective chart review Key Findings::
- 64 IBS-SIBO patients with confirmed clinical and breath test resolution post-antibiotic treatment
- Symptom-free days before relapse: no prevention 59.7 days; low-dose nocturnal erythromycin 138.5 days; low-dose nocturnal tegaserod 241.6 days
- Tegaserod significantly superior to erythromycin (p\<0.05) and to no prevention
- Mechanism: prokinetics stimulate MMC phase III contractions, maintaining fasting clearance of small intestinal contents
- Note: tegaserod withdrawn from US market (cardiac risk); prucalopride is the current functional replacementConclusion:: Post-eradication prokinetics meaningfully extend relapse-free intervals in IBS-SIBO, supporting their routine use to address the underlying motility deficit. Limitations:: Retrospective, small subgroups (tegaserod n=16), no blinding, IBS-SIBO proxy for ME/CFS. Tegaserod unavailable; evidence does not directly apply to prucalopride (assumed class effect). Single-centre. ME/CFS Relevance:: Directly supports the clinical strategy of prokinetic prophylaxis after SIBO eradication in ME/CFS patients with autonomic/MMC dysfunction. Addresses the root-cause gap: without restoring MMC function, antibiotic-treated SIBO will recur within 2–3 months. Certainty Assessment::
- *Quality:* Low--Medium (retrospective, small groups)
- *Sample:* n=64 (subgroups n=16--42)
- *Replication:* Not independently replicated
- *Score:* 0.354 Deloose et al. 2012 — Migrating Motor Complex: Control and Disease
Full Citation:: Deloose E, Janssen P, Depoortere I, Tack J. The migrating motor complex: control mechanisms and its role in health and disease. Nat Rev Gastroenterol Hepatol. 2012;9(5):271–285. (Deloose et al. 2012) DOI:: 10.1038/nrgastro.2012.57 PMID:: 22450306 Article Type:: Comprehensive narrative review (Nature Reviews) Key Findings::
- MMC is a cyclic fasting motility pattern (4 phases; phase III = powerful peristaltic sweep every 90--120 min)
- MMC absence definitively associated with gastroparesis, intestinal pseudo-obstruction, and SIBO
- Critical mechanistic distinction: vagus nerve modulates *gastric* MMC phase III but does NOT regulate small bowel MMC periodicity (enteric nervous system autonomous)
- Motilin, ghrelin, erythromycin induce antro-duodenal phase III; serotonin and somatostatin induce duodenal-origin phase III
- Scintigraphy and electrophysiology studies confirm enteric autonomy of small bowel MMCConclusion:: MMC dysfunction is a central mechanism linking gut dysmotility to SIBO. The enteric nervous system dominates small bowel MMC; autonomic vagal dysfunction is a contributing but not sufficient cause of MMC failure in ME/CFS. Limitations:: Review article, no primary data. Does not address ME/CFS specifically. Mechanistic understanding of enteric neuropathy in ME/CFS remains incomplete. ME/CFS Relevance:: Establishes the mechanistic foundation for the vagal dysfunction → MMC impairment → SIBO pathway in ME/CFS. Clarifies that the autonomic component is primarily gastric; small bowel MMC failure likely requires additional enteric neuropathy. This nuance prevents oversimplification of the ME/CFS-SIBO pathway. Certainty Assessment::
- *Quality:* High (Nature Reviews Gastroenterology, comprehensive and widely cited)
- *Sample:* Review (no primary cohort)
- *Replication:* Mechanisms well-replicated in referenced primary studies
- *Score:* 0.805 Szabo et al. 2014 — H2S and Mitochondrial Complex IV Inhibition
Full Citation:: Szabo C, Ransy C, Módis K, Andriamihaja M, Murghes B, Coletta C, Olah G, Yanagi K, Bouillaud F. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms. Br J Pharmacol. 2014;171(8):2099–2122. (Szabo et al. 2014) DOI:: 10.1111/bph.12369 PMID:: 23991830 Article Type:: Biochemical review with experimental evidence Key Findings::
- H2S has a biphasic (bell-shaped) relationship with mitochondrial function
- At low-physiological concentrations: H2S donates electrons via sulfide:quinone oxidoreductase (SQR) → stimulates electron transport chain → increases ATP production
- At high-toxic concentrations: H2S competitively binds to cytochrome a3 prosthetic group of Complex IV (cytochrome c oxidase) → blocks O2 binding → electron backup throughout ETC → inner membrane potential collapses → aerobic ATP synthesis ceases
- Mechanism is functionally identical to cyanide poisoning at high doses
- Colonocytes normally metabolise H2S as a barrier, preventing systemic absorption; intestinal sulfide overproduction (ISO) overwhelms this protection
- SQR-mediated H2S oxidation integrates H2S into the ETC as an electron donor — dual substrate and inhibitor depending on concentrationConclusion:: H2S-dominant SIBO (ISO) creates a local gut environment of chronically elevated H2S that, when systemic exposure occurs, directly inhibits mitochondrial Complex IV with consequences for ATP generation — a plausible mechanism connecting gut dysbiosis to ME/CFS-pattern energy failure. Limitations:: Biochemical review; direct demonstration of SIBO-derived H2S inhibiting patient mitochondria has not been performed in ME/CFS cohorts. The concentration thresholds for stimulation vs inhibition are not fully characterized in vivo. ME/CFS Relevance:: Provides the mechanistic bridge for the SIBO-derived H2S → Complex IV inhibition → reduced aerobic ATP → fatigue pathway. Directly connects the gut-microbiome chapter to the energy-metabolism and mitochondrial dysfunction chapters. H2S-dominant SIBO subtype (ISO) warrants specific identification and treatment in ME/CFS patients with fatigue disproportionate to other findings. Certainty Assessment::
- *Quality:* High (British Journal of Pharmacology, mechanistic review with experimental grounding)
- *Sample:* Biochemical studies (multiple)
- *Replication:* Core mechanism well-replicated; SIBO-ME/CFS application is inference
- *Score:* 0.806 Rezaie et al. 2017 — North American Consensus on Breath Testing
Full Citation:: Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American Consensus. Am J Gastroenterol. 2017;112(5):775–784. (Rezaie et al. 2017) DOI:: 10.1038/ajg.2017.46 PMID:: 28323273 Article Type:: Expert consensus statement Key Findings::
- 26 consensus statements across five domains: indications, preparation, performance, result interpretation, knowledge gaps
- SIBO positive threshold: hydrogen rise ≥20 ppm by 90 min on glucose or lactulose BT
- Methane (IMO) positive: ≥10 ppm at any time point
- Recommended substrate doses: lactulose 10 g, glucose 75 g, fructose 25 g, lactose 25 g
- Standard 2-gas devices do not measure H2S — identified explicitly as a knowledge gap (predates trio-smart)
- Not recommended for oro-cecal transit measurement (transit-time confounding)Conclusion:: Establishes the diagnostic standard for hydrogen/methane breath testing 2017–present. Explicitly acknowledges H2S as an unmeasured gap, creating the clinical rationale for trio-smart development. Limitations:: Consensus, not systematic review. Lactulose test specificity questioned by subsequent ESNM/ANMS critique (Kashyap 2024). H2S/ISO detection still requires specialised equipment not widely available. Consensus group includes Pimentel, whose commercial ties to breath test technology represent a potential COI. ME/CFS Relevance:: Defines the diagnostic standards that should be applied when breath testing ME/CFS patients for SIBO. Critical for interpreting the Karhu 2023 prevalence data. The H2S gap means existing ME/CFS prevalence studies may systematically undercount ISO-dominant patients. Certainty Assessment::
- *Quality:* High (multi-expert consensus, American Journal of Gastroenterology)
- *Sample:* Expert consensus (no primary cohort)
- *Replication:*: Widely adopted as standard; partially critiqued by Kashyap 2024
- *Score:* 0.757 Pimentel et al. 2020 — ACG Clinical Guideline: SIBO
Full Citation:: Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115(2):165–178. (Pimentel et al. 2020) DOI:: 10.14309/ajg.0000000000000501 PMID:: 32023228 Article Type:: Clinical practice guideline (GRADE methodology) Key Findings::
- GRADE-based guideline covering diagnosis, testing, and treatment of SIBO
- Breath testing recommended for IBS, symptomatic motility disorders, and post-GI-surgery patients
- Rifaximin 550 mg TID × 14 days: first-line for H2-dominant SIBO
- Rifaximin + neomycin: for CH4-dominant (intestinal methanogenic overgrowth, IMO)
- Nutrient malabsorption mechanisms documented: vitamin B12 (bacterial competitive consumption before intrinsic-factor-bound B12 reaches terminal ileum), fat-soluble vitamins A/D/E/K (bacterial deconjugation of bile salts → fat maldigestion), iron (mucosal inflammation + competitive uptake)
- Prokinetics post-eradication mentioned as prevention strategy
- Predisposing conditions include motility disorders, anatomical abnormalities, immunodeficiency — all relevant to ME/CFSConclusion:: Comprehensive evidence-based guidance for SIBO management applicable to ME/CFS patients with GI comorbidity. Formalises the nutrient malabsorption consequences that compound ME/CFS-related deficiency burden. Limitations:: GRADE evidence base is limited for many recommendations; much relies on expert opinion. First-author (Pimentel) has commercial interest in SIBO breath testing field. H2S/ISO not yet addressed (predates wider trio-smart use). ME/CFS Relevance:: Gold-standard reference for SIBO treatment decisions in ME/CFS clinic. Nutrient malabsorption section directly explains why ME/CFS patients with untreated SIBO accumulate B12, iron, and fat-soluble vitamin deficiencies that worsen fatigue, cognitive symptoms, and immune dysfunction independent of primary ME/CFS pathology. Certainty Assessment::
- *Quality:* High (ACG official guideline, GRADE methodology)
- *Sample:* Guideline (synthesises multiple studies)
- *Replication:*: Widely adopted; evidence graded per GRADE
- *Score:* 0.808 Wielgosz-Grochowska et al. 2024 — SIBO Subtypes and Nutritional Status
Full Citation:: Wielgosz-Grochowska JP, Domanski N, Drywien ME. Identification of SIBO subtypes along with nutritional status and diet as key elements of SIBO therapy. Int J Mol Sci. 2024;25(13):7341. (Wielgosz-Grochowska, Domanski, and Drywien 2024) DOI:: 10.3390/ijms25137341 PMID:: 39000446 Article Type:: Observational cross-sectional study Key Findings::
- n=67 newly diagnosed SIBO patients: H+ 18%, M+ 31%, H+/M+ mixed 51%
- H+/M+ group: lowest serum vitamin D, lowest serum ferritin (iron stores), highest dietary fat intake; most pronounced deficiency burden
- M+ group: elevated serum folate (bacterial production of folate as byproduct), reduced fibre intake
- H+ group: primary abnormality was reduced lactose tolerance
- 87--97% of all subtypes below vitamin D adequate intake threshold
- Over 70% of M+ and H+/M+ groups consumed excessive dietary fat
- Conclusion: SIBO subtype determines specific nutritional deficiency profile; subtype-guided supplementation requiredConclusion:: SIBO subtype is clinically meaningful for nutritional assessment. Mixed H+/M+ patients carry the greatest deficiency burden, particularly for vitamin D and iron — nutrients already commonly deficient in ME/CFS. Limitations:: Small n (67), single-centre (Warsaw, Poland), observational design with no control group. Not ME/CFS-specific. Polish cohort dietary patterns may not generalize. Serum vitamin D reflects sun exposure and supplementation as well as gut absorption. ME/CFS Relevance:: Quantifies subtype-specific deficiency profiles directly relevant to ME/CFS patients with SIBO comorbidity. Low ferritin and vitamin D in the mixed subtype compound the energy-metabolism and immune-dysfunction burden in ME/CFS. Supports routine subtype testing and targeted repletion rather than empirical supplementation alone. Certainty Assessment::
- *Quality:* Medium (observational, single-centre, small n)
- *Sample:* n=67
- *Replication:* Not independently replicated
- *Score:* 0.459 Kashyap et al. 2024 — Critical Appraisal of SIBO Hypothesis (ESNM/ANMS)
Full Citation:: Kashyap P, Moayyedi P, Quigley EMM, Simren M, Vanner S. Critical appraisal of the SIBO hypothesis and breath testing: a clinical practice update endorsed by the European Society of Neurogastroenterology and Motility (ESNM) and the American Neurogastroenterology and Motility Society (ANMS). Neurogastroenterol Motil. 2024;36(6):e14817. (Kashyap et al. 2024) DOI:: 10.1111/nmo.14817 PMID:: 38798120 | PMC: PMC11268457 Article Type:: Clinical practice update / critical appraisal (endorsed by two major societies) Key Findings::
- Core conclusion: "after two decades, this hypothesis remains unproven"
- Primary methodological flaw: lactulose H2 breath test (LHBT) measures oro-cecal transit, not small intestinal bacterial counts; normal transit range (25--200 min) generates widespread false positives
- Three independent research teams found no time point discriminates IBS patients from healthy controls on LHBT
- Diagnostic cut-off criteria (20 ppm, 90 min; later 180 min; adding methane, H2S) changed repeatedly without prospective validation
- Breath test normalization does not reliably predict clinical improvement — the claimed mechanistic link is unconfirmed
- Injudicious antibiotic prescribing driven by unvalidated testing raises antimicrobial resistance concernsConclusion:: The SIBO-as-cause-of-IBS hypothesis and the diagnostic value of standard breath testing for IBS are not supported by evidence. Recommends rejecting the hypothesis and curtailing breath-test-driven antibiotic prescribing. Limitations:: Critique focuses on IBS; does not address ME/CFS-specific data. Does not negate the existence of SIBO as a pathological condition or its prevalence in other populations. Some panelists may have publication bias against the SIBO hypothesis. The Karhu 2023 ME/CFS data (referral-based cohort with confirmed breath test) is not directly addressed. ME/CFS Relevance:: Essential counter-evidence. Mandates that breath-test-based SIBO prevalence data in ME/CFS (Karhu 2023; Pimentel 2000) be interpreted cautiously given unresolved test validity concerns. Supports use of breath testing only as an adjunct, not a standalone diagnostic tool, and prevents overclaiming SIBO as a core ME/CFS mechanism without stronger evidence. Certainty Assessment::
- *Quality:* High (endorsed by ESNM and ANMS, rigorous methodology critique)
- *Sample:* Appraisal of multiple studies
- *Replication:*: Consistent with independent critiques of breath test validity
- *Score:* 0.80